New Zealand’s PHARMAC Declines Funding For Roche’s Herceptin 12-Month Treatment For Early HER2 Positive Patients
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - New Zealand's Pharmaceutical Management Agency has decided to decline funding for Roche's Herceptin (trastuzumab) for 12-month treatment for HER2-positive early breast cancer treatment, the agency announced Aug. 7